GSK-3 inhibitors and their potential in the treatment of Alzheimer’s disease

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.15, Iss.10, 2005-10, pp. : 1315-1331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease

Current Pharmaceutical Design, Vol. 16, Iss. 25, 2010-08 ,pp. : 2790-2798

Bentham Science Publishers

Access to resources Recommend Favorite

Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review

Current Topics in Medicinal Chemistry, Vol. 17, Iss. 31, 2018-02 ,pp. : 3361-3369

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimers Disease

By Jönsson L.

PharmacoEconomics, Vol. 21, Iss. 14, 2003-01 ,pp. : 1025-1037

Adis International

Access to resources Recommend Favorite

Acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease

By Gauthier S.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1511-1520

Informa Healthcare

Access to resources Recommend Favorite

Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease

By Beher Dirk Graham Samuel L

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 11, 2005-11 ,pp. : 1385-1409

Informa Healthcare

Access to resources Recommend Favorite